TABLE 3.
Partial correlation analysis between Lewy body-associated proteins levels and clinical characteristics scores.
| Clinical scales | p-Asyn ser129 (ng/ml) | Total α -syn (ng/ml) | Oligomeric α -syn (ng/ml) |
| Total UPDRS | −0.155 (0.288) | −0.171 (0.240) | −0.084 (0.566) |
| UPDRS I | 0.126 (0.390) | 0.113 (0.439) | 0.064 (0.663) |
| UPDRS II | −0.083 (0.573) | −0.161 (0.270) | −0.159 (0.275) |
| UPDRS III | −0.210 (0.148) | −0.176 (0.225) | −0.035 (0.811) |
| UPDRS IV | −0.026 (0.859) | −0.096 (0.513) | −0.100 (0.494) |
| Hoehn–Yahr stage | −0.272 (0.059) | −0.223 (0.108) | −0.093 (0.526) |
| MMSE | 0.204 (0.160) | 0.225 (0.119) | −0.192 (0.185) |
| HAMD | 0.105 (0.474) | 0.079 (0.587) | 0.025 (0.863) |
| HAMA | −0.048 (0.745) | 0.076 (0.604) | 0.084 (0.564) |
| RBDQ-HK | 0.036 (0.806) | −0.122 (0.402) | −0.141 (0.334) |
UPDRS, unified Parkinson’s disease rating scale; MMSE, mini-mental state examination; HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale; RBDQ-HK, REM sleep behavior disorder questionnaire – Hong Kong.